BiotechTube

Ekmasonid + Uceris (first dose) + Uceris (second dose)

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Sep 17, 2020 → Dec 4, 2020

NCT ID
NCT04854538

About Ekmasonid + Uceris (first dose) + Uceris (second dose)

Ekmasonid + Uceris (first dose) + Uceris (second dose) is a phase 1 stage product being developed by Hikma Pharmaceuticals for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT04854538. Target conditions include Healthy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04854538Phase 1Completed

Competing Products

20 competing products in Healthy

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Hikma Pharmaceuticals

Pemetrexed + ErlotinibApproved
80
praziquantelPhase 3
72
DasatinibPhase 2
47
Sphingomod + GilenyaPhase 1
28
Azacitidine + OnuregPhase 1
28